Menveo (Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M)

• Menveo is a conjugate vaccine that targets the capsular polysaccharides of Neisseria meningitidis, providing protection against invasive meningococcal disease.
• Invasive meningococcal disease (serogroups A, C, W‑135, Y): Provides active immunity to prevent infection.
• Travel to endemic regions: Reduces risk of acquiring meningococcal disease during travel.
• Adolescents and young adults: Offers protection for high‑risk age groups.

• The conjugated oligosaccharide antigens are covalently linked to the CRM197 carrier protein, enabling the vaccine to be processed by antigen‑presenting cells and to stimulate T‑cell–dependent B‑cell responses. This results in the production of high‑affinity antibodies that recognize the capsular polysaccharides of Neisseria meningitidis serogroups A, C, W‑135 and Y, thereby preventing bacterial invasion and disease.

Common side effects are generally mild and resolve without medical intervention.

Common Side Effects

• Injection site pain: mild to moderate soreness at the injection site.
• Redness or swelling: localized erythema or edema.
• Fever: transient low‑grade temperature elevation.
• Headache: mild headache occurring within 24 hours.
• Fatigue: temporary feeling of tiredness.
• Muscle aches: mild myalgia after vaccination.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rapid onset of hives, airway swelling, hypotension.
• Guillain‑Barré syndrome: rare neurological disorder causing muscle weakness.
• Seizures: infrequent occurrence of convulsive episodes.
• High fever (>40 °C): persistent high temperature requiring medical attention.
• Serum sickness‑like reaction: rash, joint pain, fever.
• Neurological complications: rare cases of meningitis or encephalitis.

• Before administering Menveo, consider the following precautions to ensure safe use.
• Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component.
• Medical history review: defer vaccination in persons with severe immunodeficiency.
• Pregnancy consideration: discuss risks and benefits with healthcare provider.
• Concurrent illness: postpone vaccination if acute moderate or severe illness is present.
• Post‑vaccination observation: monitor for at least 15 minutes for immediate reactions.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Menveo may interact with certain therapies or vaccines; review patient medication history.

Major Interactions (Avoid)

• Live bacterial vaccines: concurrent administration may reduce immune response; separate by at least 4 weeks.
• Immunoglobulin therapy: may interfere with vaccine efficacy; postpone vaccination for 3 months after therapy.
• Blood products containing anti‑meningococcal antibodies: avoid within 6 weeks.

Moderate Interactions (Monitor Closely)

• Antipyretics (acetaminophen, ibuprofen): may mask fever, monitor for underlying reaction.
• Immunosuppressive drugs (e.g., corticosteroids): may diminish antibody response; assess immunity post‑vaccination.
• Other vaccines administered simultaneously: monitor for additive local reactions.